QLT Faces $70M Bill From Visudyne Ruling
A judge has ruled that QLT Inc. is liable for unjust enrichment and unfair trade practices in a patent dispute over eye treatment Visudyne, which could cost the biopharmaceutical company $69.6...To view the full article, register now.
Already a subscriber? Click here to view full article